Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2J2 | P51589 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | CCR3 | P51677 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050713 | 0.91 | CCR3 (0.66) | CCR3 | |
| Hydrochloric Acid SCHEMBL9053162 | 0.90 | CCR3 (0.65) | CCR3 | |
| SCHEMBL4512783 | 0.88 | DRD2 (0.71) | CCR3 | |
| Hydrochloric Acid SCHEMBL7303580 | 0.87 | DRD2 (0.69) | CCR3 | |
| SCHEMBL17023763 | 0.85 | CYP2J2 (0.70) | CYP2J2SLC6A2SLC6A4CCR3 | |
| SCHEMBL11678538 | 0.83 | KDM4E (0.59) | SLC6A2SLC6A4CCR3 | |
| SCHEMBL7012490 | 0.82 | CCR3 (0.67) | SLC6A2SLC6A4CCR3 | |
| SCHEMBL11548949 | 0.82 | GRIN2B (0.55) | SLC6A2SLC6A4CCR3 | |
| SCHEMBL11679317 | 0.82 | GRIN2B (0.55) | SLC6A2SLC6A4CCR3 | |
| SCHEMBL7532115 | 0.81 | GRIN2B (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485651-B2 | Compounds with activity on muscarinic receptors | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| CN-1303376-A | Compound with activity on muscarinic receptors | ACADIA PHARMACEUTICAL INC (US) | 2001-07-11 | — | — | CN | disclosed |
| WO-2001005763-A2 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | CYP2J2 1975/4885SLC6A2 998/4885SLC6A4 1516/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | CYP2J2 1975/4885SLC6A2 998/4885SLC6A4 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.